{"disease":{"id":"radioiodine-refractory-differentiated-thyroid-cancer","name":"radioiodine refractory differentiated thyroid cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07068542","title":"Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT06898437","title":"Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}